BRIDGEWAY CAPITAL MANAGEMENT, LLC

Position in ANNX — Annexon, Inc.

CIK 1107261 HOUSTON, TX

Position in ANNX

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$541,812

-$149,944 QoQ

Shares Held

97,800

-29.0% QoQ

Ownership

0.049%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2023

10 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

BRIDGEWAY CAPITAL MANAGEMENT, LLC holds $59,315,164 across 112 Biotechnology names. ANNX ranks #28 (0.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	GLUE	Monte Rosa Therapeutics, Inc.	528,698	$8,697,082
2	PBYI	Puma Biotechnology, Inc.	775,341	$4,954,428
3	EXEL	Exelixis, Inc.	66,100	$2,835,029
4	KROS	Keros Therapeutics, Inc.	195,017	$2,152,987
5	SGMT	Sagimet Biosciences Inc.	299,641	$1,565,624
6	BDTX	Black Diamond Therapeutics, Inc.	723,477	$1,541,006
7	PTCT	Ptc Therapeutics, Inc.	22,000	$1,498,860
8	KYTX	Kyverna Therapeutics, Inc.	149,900	$1,293,637

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$541,812	97,800	-29.0%	Shares	Sole	2026-05-15
2025-12-31	$691,756	137,800	0.0%	Shares	Sole	2026-02-17
2025-09-30	$420,290	137,800	+40.9%	Shares	Sole	2025-11-14
2025-06-30	$234,720	97,800	+95.6%	Shares	Sole	2025-08-14
2024-09-30	$296,000	50,000	-41.2%	Shares	Sole	2024-11-14
2024-06-30	$416,500	85,000	-52.1%	Shares	Sole	2024-08-14
2024-03-31	$1,272,675	177,500	-1.1%	Shares	Sole	2024-05-15
2023-12-31	$814,930	179,500	+8.7%	Shares	Sole	2024-02-14
2023-09-30	$389,636	165,100	+78.5%	Shares	Sole	2023-11-14
2023-06-30	$325,600	92,500	—	Shares	Sole	2023-08-14
No filing history on record for this holder in this stock.